S&P Futures
6,006.75 +0.25 (+0.00%) Dow Futures
44,836.00 +10.00 (+0.02%) Nasdaq Futures
20,897.25 +17.00 (+0.08%) Russell 2000 Futures
2,442.20 -8.80 (-0.36%) Crude Oil
69.23 +0.29 (+0.42%) Gold
2,623.50 +5.00 (+0.19%)
Nxera Pharma Co., Ltd. (SOLTF)
| Previous Close | 0.00 |
| Open | 7.75 |
| Bid | 7.80 x 40000 |
| Ask | 7.30 x 40000 |
| Day's Range | 7.75 - 7.75 |
| 52 Week Range | 7.00 - 13.43 |
| Volume | |
| Avg. Volume | 121 |
| Market Cap | 723.884M |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.27 |
| Earnings Date | Feb 11, 2025 - Feb 17, 2025 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Mar 27, 2015 |
| 1y Target Est | N/A |
GlobeNewswireNxera Pharma and Antiverse Enter Collaboration To Design Novel GPCR-Targeted Antibody Therapeutics Using Generative AI
Tokyo, Japan and London and Cardiff, UK, 5 November 2024 – Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). The collaboration combines Antiverse’s generative AI antibody design expertise, including its proprietary machine-learning-generated ‘epitope-s
- GlobeNewswire
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2024
Tokyo, Japan and Cambridge, UK, 1 November 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended on 30 September 2024. The full report can be viewed here. Chris Cargill, President & CEO of Nxera, commented: “The third quarter of 2024 has seen Nxera reach two important product development milestones. First, i
